RecruitingPhase 1Phase 2NCT06843408

A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD

A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease After Systemic Therapy

Sponsor

Incyte Corporation

Enrollment

30 participants

Start Date

Jun 25, 2025

Study Type

INTERVENTIONAL

Conditions

Chronic Graft Versus Host Disease

Summary

This study will be conducted to evaluate the safety, efficacy, and pharmacokinetics of axatilimab monotherapy in Chinese participants with recurrent or refractory active chronic graft-versus-host disease after systemic therapy.

Eligibility

Min Age: 12 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called INCA034176 for people with chronic graft versus host disease. The study is currently recruiting participants at 9 locations. People eligible for this study include aged 12 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGINCA034176

IV infusion

Locations(9)

Peking University People'S Hospital

Beijing, China

West China Hospital of Sichuan University

Chengdu, China

The Second Affiliated Hospital, Army Medical University (Xinqiao Hospital)

Chongoing, China

Zhujiang Hospital of Southern Medical University

Guangzhou, China

Nanfang Hospital of Southern Medical University

Guangzhou, China

The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, China

Shanghai Children'S Medical Center

Shanghai, China

Institute of Hematology, Chinese Academy of Medical Sciences

Tianjin, China

Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology

Wuhan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06843408

Related Trials

Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease

NCT066637223 locations

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

NCT059966275 locations